Aardvark Therapeutics, Inc. (AARD)
Nasdaq · Pharmaceutical Preparations · Inc. DE
What they're doing
Between 7 June 2026 and 5 September 2026, Aardvark Therapeutics, Inc. filed a single 8-K report on 12 June 2026 disclosing a change in its director or officer structure. No additional details regarding the nature of the change—whether an appointment, resignation, or other modification—are provided in the available data. The company, which operates in the pharmaceutical preparations sector, recorded no government contracts during the trailing 24-month period, and no lobbying activity was reported for the most recent quarter. No other material corporate actions, regulatory filings, or public events were recorded during this three-month window. The limited data reflects a relatively quiet period for publicly disclosed corporate activity beyond the single leadership change reported in mid-June.
Generated 2026-09-05 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing director or officer change
- Insider purchaseLee Tien-Li (director) bought $101k of stock
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-11 | Sun Nelson | officer | S | 62,000 | 5.18 | $321,179 |
| 2026-09-10 | Sun Nelson | officer | S | 14,754 | 5 | $73,779 |
| 2025-12-11 | Sun Nelson | officer | P | 3,000 | 14.4 | $43,200 |
| 2025-12-11 | Lee Tien-Li | director | P | 7,000 | 14.49 | $101,430 |
| 2025-12-11 | Sun Nelson | officer | P | 3,000 | 14.4 | $43,200 |
| 2025-12-11 | Lee Tien-Li | director | P | 7,000 | 14.49 | $101,395 |
| 2025-10-15 | Lee Tien-Li | director | M | 1,229 | 4.24 | $5,211 |
| 2025-10-15 | Jones Bryan | officer | M | 1,250 | 4.24 | $5,300 |
| 2025-10-15 | Lee Tien-Li | director | M | 1,229 | 4.24 | $5,211 |
| 2025-10-15 | Jones Bryan | officer | M | 1,250 | 4.24 | $5,300 |
| 2025-09-15 | Lee Tien-Li | director | P | 6,500 | 9.51 | $61,815 |
| 2025-09-15 | Lee Tien-Li | director | P | 3,500 | 9.94 | $34,790 |
| 2025-09-15 | Lee Tien-Li | director | P | 6,500 | 9.51 | $61,819 |
| 2025-09-15 | Lee Tien-Li | director | P | 3,500 | 9.94 | $34,805 |
| 2025-09-12 | Lee Tien-Li | director | P | 5,000 | 8.5 | $42,500 |
| 2025-09-12 | Lee Tien-Li | director | P | 5,000 | 8.5 | $42,516 |
| 2025-09-11 | Lee Tien-Li | director | P | 6,000 | 7.82 | $46,920 |
| 2025-09-11 | Lee Tien-Li | director | P | 6,000 | 7.82 | $46,926 |
| 2025-09-10 | Lee Tien-Li | director | P | 9,000 | 7.91 | $71,190 |
| 2025-09-10 | Lee Tien-Li | director | P | 9,000 | 7.91 | $71,213 |
| 2025-09-09 | Sun Nelson | officer | P | 6,000 | 8.07 | $48,420 |
| 2025-09-09 | Sun Nelson | officer | P | 6,000 | 8.07 | $48,440 |
| 2025-08-28 | Lee Tien-Li | director | M | 17,209 | 4.24 | $72,966 |
| 2025-08-28 | Lee Tien-Li | director | M | 17,209 | 4.24 | $72,966 |
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P. | ten percent owner | C | 2,333,887 | — | — |
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P. | ten percent owner | P | 625,000 | 16 | $10,000,000 |
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P. | ten percent owner | P | 625,000 | 16 | $10,000,000 |
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P. | ten percent owner | C | 333,412 | — | — |
| 2025-02-14 | Chi Jeffrey | director | C | 133,364 | — | — |
| 2025-02-14 | Vickers Venture Fund VI Pte Ltd | ten percent owner | C | 1,637,411 | — | — |
| 2025-02-14 | Vickers Venture Fund VI Pte Ltd | ten percent owner | C | 413,491 | — | — |
| 2025-02-14 | Lee Tien-Li | director | P | 16,542 | 16 | $264,672 |
| 2025-02-14 | Lee Tien-Li | director | C | 41,303 | — | — |
| 2025-02-14 | Sun Nelson | officer | P | 10,000 | 16 | $160,000 |
| 2025-02-14 | Sun Nelson | officer | C | 7,001 | — | — |
| 2025-02-14 | Chen Bihua | other | P | 187,500 | 16 | $3,000,000 |
| 2025-02-14 | Chen Bihua | other | C | 800,189 | — | — |
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P.; Decheng Capital Management IV (Cayman), LLC; Decheng Capital Global Healthcare Fund (Master), LP; Decheng Capital Global Healthcare GP, LLC; Cui Xiangmin | ten percent owner | C | 2,333,887 | — | — |
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P.; Decheng Capital Management IV (Cayman), LLC; Decheng Capital Global Healthcare Fund (Master), LP; Decheng Capital Global Healthcare GP, LLC; Cui Xiangmin | ten percent owner | C | 333,412 | — | — |
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P.; Decheng Capital Management IV (Cayman), LLC; Decheng Capital Global Healthcare Fund (Master), LP; Decheng Capital Global Healthcare GP, LLC; Cui Xiangmin | ten percent owner | P | 625,000 | 16 | $10,000,000 |
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P.; Decheng Capital Management IV (Cayman), LLC; Decheng Capital Global Healthcare Fund (Master), LP; Decheng Capital Global Healthcare GP, LLC; Cui Xiangmin | ten percent owner | P | 625,000 | 16 | $10,000,000 |
| 2025-02-14 | Chi Jeffrey | director | C | 133,364 | — | — |
| 2025-02-14 | Vickers Venture Fund VI Pte Ltd | ten percent owner | C | 1,637,411 | — | — |
| 2025-02-14 | Vickers Venture Fund VI Pte Ltd | ten percent owner | C | 413,491 | — | — |
| 2025-02-14 | Lee Tien-Li | director | C | 41,303 | — | — |
| 2025-02-14 | Lee Tien-Li | director | P | 16,542 | 16 | $264,672 |
| 2025-02-14 | Sun Nelson | officer | C | 7,001 | — | — |
| 2025-02-14 | Sun Nelson | officer | P | 10,000 | 16 | $160,000 |
| 2025-02-14 | Cormorant Asset Management, LP; Chen Bihua | other | C | 800,189 | — | — |
| 2025-02-14 | Cormorant Asset Management, LP; Chen Bihua | other | P | 187,500 | 16 | $3,000,000 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.